FCF Life Sciences acts as sole financial advisor to Precisis AG in a EUR 20m financing round with Cochlear Ltd.

Munich, 11th October 2021 – FCF Life Sciences, part of FCF Fox Corporate Finance GmbH, acts as sole financial advisor to Precisis AG, a leading neurostimulation company, in the execution of a financing transaction of EUR 20m with Cochlear Ltd., the global leader in implantable hearing solutions.

The FCF Life Sciences team advised Precisis and its shareholders on a EUR 20m financing transaction with Cochlear Ltd. Precisis is developing next-gen medical devices in the field of neurostimulation to improve the lives of patients suffering from epilepsy.

The funding will be used to support Precisis’ ongoing clinical trials and commercialization. In addition, the product development of the implantable bioelectric brain stimulation system, which explores novel approaches to treating epilepsy, will be supported under the collaboration.

Dr. Mathias Schott, Head of FCF Life Sciences, commented: “We are pleased having initiated the collaboration between Precisis AG and Cochlear Ltd. Precisis is gaining a very valuable strategic partner for its growth plans. On the other hand, Cochlear is adding a highly innovative technology to its portfolio.”

The collaboration will leverage the demonstrated ability to trigger a paradigm shift in brain stimulation by the Precisis technology and benefit from Cochlear’s deep expertise in the stimulation field as well as strong commercial track record.

FCF Fox Corporate Finance GmbH acted as sole financial advisor to Precisis.

Precisis press release

Case study Precisis AG

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: